Literature DB >> 17656365

Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.

Hong Wu1, Ludmila Dombrovsky, Wolfram Tempel, Fernando Martin, Peter Loppnau, Geoffrey H Goodfellow, Denis M Grant, Alexander N Plotnikov.   

Abstract

The human arylamine N-acetyltransferases NAT1 and NAT2 play an important role in the biotransformation of a plethora of aromatic amine and hydrazine drugs. They are also able to participate in the bioactivation of several known carcinogens. Each of these enzymes is genetically variable in human populations, and polymorphisms in NAT genes have been associated with various cancers. Here we have solved the high resolution crystal structures of human NAT1 and NAT2, including NAT1 in complex with the irreversible inhibitor 2-bromoacetanilide, a NAT1 active site mutant, and NAT2 in complex with CoA, and have refined them to 1.7-, 1.8-, and 1.9-A resolution, respectively. The crystal structures reveal novel structural features unique to human NATs and provide insights into the structural basis of the substrate specificity and genetic polymorphism of these enzymes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656365     DOI: 10.1074/jbc.M704138200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Comparison of the Arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis.

Authors:  Elizabeth Fullam; Akane Kawamura; Helen Wilkinson; Areej Abuhammad; Isaac Westwood; Edith Sim
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

Review 2.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

3.  Xenobiotic-metabolizing enzymes in Bacillus anthracis: molecular and functional analysis of a truncated arylamine N-acetyltransferase isozyme.

Authors:  Xavier Kubiak; Romain Duval; Benjamin Pluvinage; Alain F Chaffotte; Jean-Marie Dupret; Fernando Rodrigues-Lima
Journal:  Br J Pharmacol       Date:  2016-11-12       Impact factor: 8.739

4.  Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad.

Authors:  Xavier Kubiak; Inès Li de la Sierra-Gallay; Alain F Chaffotte; Benjamin Pluvinage; Patrick Weber; Ahmed Haouz; Jean-Marie Dupret; Fernando Rodrigues-Lima
Journal:  J Biol Chem       Date:  2013-06-16       Impact factor: 5.157

5.  Probing the catalytic potential of the hamster arylamine N-acetyltransferase 2 catalytic triad by site-directed mutagenesis of the proximal conserved residue, Tyr190.

Authors:  Xin Zhou; Naixia Zhang; Li Liu; Kylie J Walters; Patrick E Hanna; Carston R Wagner
Journal:  FEBS J       Date:  2009-10-23       Impact factor: 5.542

Review 6.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 7.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

Review 8.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

9.  Insights into how protein dynamics affects arylamine N-acetyltransferase catalysis.

Authors:  Naixia Zhang; Kylie J Walters
Journal:  Biochem Biophys Res Commun       Date:  2009-05-20       Impact factor: 3.575

Review 10.  Arylamine N-acetyltransferases in mycobacteria.

Authors:  Edith Sim; James Sandy; Dimitrios Evangelopoulos; Elizabeth Fullam; Sanjib Bhakta; Isaac Westwood; Anna Krylova; Nathan Lack; Martin Noble
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.